Assembly Biosciences (ASMB) vs Monopar Therapeutics (MNPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Monopar Therapeutics (MNPR) has outperformed Assembly Biosciences (ASMB) over the past year, losing 24.6% versus a loss of 42.4%. Over five years, MNPR leads with a +184.5% price change compared with -21.3% for ASMB. Monopar Therapeutics is the larger company by market cap ($467.6 million vs $454.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | MNPR |
|---|---|---|
| Share price | $22.19 | $69.00 |
| Market cap | $454.39M | $467.60M |
| 1-day change | -1.38% | -1.84% |
| YTD return | -34.75% | +5.67% |
| 1-year return | -42.36% | -24.64% |
| 5-year return | -21.31% | +184.54% |
| P/E ratio (TTM) | 29.59 | — |
| EPS (TTM) | $0.75 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.30M | $0 |
| Revenue growth (YoY) | +153.52% | — |
| Net income (latest FY) | $-6.12M | $-13.72M |
| Operating margin | -16.76% | — |
| Net margin | -8.47% | — |
| 52-week high | $39.65 | $124.82 |
| 52-week low | $19.20 | $50.07 |
| Distance from 52-week high | -44.04% | -44.72% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +130.73% | +88.65% |
| Average volume | 309.38K | 151.83K |
| Shares outstanding | 20.48M | 6.78M |
| Employees | 73 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNPR has outperformed ASMB by 17.7 percentage points over the past year.
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
ASMB vs MNPR FAQ
Which is bigger, Assembly Biosciences or Monopar Therapeutics?
Monopar Therapeutics (MNPR) is larger, with a market capitalization of $467.60M compared with $454.39M for Assembly Biosciences (ASMB).
Which stock has performed better over the past year, ASMB or MNPR?
MNPR returned -24.64% over the past 12 months, compared with -42.36% for ASMB (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and Monopar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.